Publicaciones en colaboración con investigadores/as de McGill University (8)

2024

  1. Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial

    Nature Medicine, Vol. 30, Núm. 1, pp. 271-278

2023

  1. Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation.

    New England Journal of Medicine, Vol. 389, Núm. 8, pp. 710-721

2018

  1. Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials

    Clinical Lung Cancer, Vol. 19, Núm. 4, pp. e465-e479

2017

  1. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: Overall survival data from the phase IIb LUX-Lung 7 trial

    Annals of Oncology, Vol. 28, Núm. 2, pp. 270-277

2016

  1. 140PD: LUX-Lung 7: A Phase IIb, global, randomised, open-label trial of afatinib vs gefitinib as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations

    Journal of Thoracic Oncology, Vol. 11, Núm. 4, pp. S117-S118

  2. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): A phase 2B, open-label, randomised controlled trial

    The Lancet Oncology, Vol. 17, Núm. 5, pp. 577-589

2011

  1. Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab

    British Journal of Cancer, Vol. 104, Núm. 1, pp. 68-74

2009

  1. Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatin

    Journal of Thoracic Oncology, Vol. 4, Núm. 11, pp. 1397-1403